MAURO GASPARINI

Scarica il contatto come vcard Foto

Professore Ordinario

Direttore (Dipartimento di Scienze Matematiche "G. L. Lagrange")
Componente (Senato Accademico)
Componente (Comitato di Ateneo per la ricerca, il trasferimento tecnologico ed i servizi al territorio)
Componente (Commissione Didattica)
Membro Centro Interdipartimentale (SmartData@PoliTO - Big Data and Data Science Laboratory)

+39 0110907510 / 7510 (DISMA)

+39 0110907546 / 7546 (DISMA)

+39 0110907552 / 7552 (DISMA)

+39 0110907554 / 7554 (DISMA)

+39 0110907556 / 7556 (DISMA)

+39 0110907558 / 7558 (DISMA)

Pagina web personale

Ambiti di ricerca
Gruppi di ricerca Statistica e Scienza dei Dati
Progetti di ricerca

Finanziati da bandi competitivi

  • Nord Ovest Digitale E Sostenibile - INDUSTRY FOR HEALTH AND SILVER ECONOMY (SPOKE 5), (2022-2025) - Responsabile Scientifico di Struttura

    PNRR – Missione 4

    ERC sectors

    LS7_1 - Medical engineering and technology PE8_13 - Industrial bioengineering PE8_5 - Fluid mechanics, hydraulic-, turbo-, and piston engines

    SDG

    Obiettivo 3. Assicurare la salute e il benessere per tutti e per tutte le età

    Abstract

    According with the scientific and technological foresight, the Spoke 5 intents to stimulate industrial research and technology transfer on two mail research line: Innovative and digital strategies for the care of frail subjects:o Telemedicine, Health and territorial health services: the pandemic was a strong stress test for the National Health System and put public hospitals under pressure. The need of involving doctors and nurses in Covid-19 patients’ cares, along with the limitation of the access to the hospitals, had a strong impact on the possibility of carrying on the regular clinical activity. This led to delayed diagnosis and worse clinical outcomes, particularly in frail subjects and in those requiring continuous follow-up for chronic conditions. Many Institutions caught this opportunity to move towards alternative ways for carrying out clinical evaluations; particularly, the tool of telemedicine, became important and its use widely adopted.However, many potentialities of telemedicine and territorial health services are still unexploited and might be developed, by enhancing the technical tools currently available. The present project aims to push the local enterprises towards the development and scale up of hardware and software, which may assist clinicians in the delivery of telemedicine, telerehabilitation and in the empowerment of territorial assistance. Beside telemedicine, the current setting strongly requires a more comprehensive way for the delivery patients’ care. New care models are required, involving clinicians, nurses and social workers, to move the assistance from the hospitals to the home of frail subjects. Indeed, the PNRR strongly underlines that the assistance should start out of the hospitals to prevent the loss of autonomy and the risk of Institutionalization. In this framework, the present project will promote the development of technological tools useful to support these novel models of care.o Digitalization and patient monitoring: the digitalization of health system is an open issue which remained unsolved for years. Only in the last decades, some steps forward have been done, but we still have a lot of work to do. Indeed, the digitalization of the health is one of the cornerstones of the PNRR and may be applied both to the generation and integration of clinical data: in this context we will aim to promote the development of wearable devices and digital tools able to monitor different physiological and functional aspects of frail subjects in their setting. Moreover, we will promote the development of platforms able to integrate comprehensively and in the respect of the individual privacy the clinical data generated.o Health prevention including nutrition, functional food and food supplements development and testing: food is a main determinant of healthy aging; in the last years, precision medicine, aiming to define a tailored approach on a single-patient basis, is developing in many different fields of medicine. Such approach might be particularly helpful also in this specific setting and we aim to give an impulse towards a tailored nutritional approach. This would require both a better definition of individual needs and the development of food supplements which may supply individual deficiencies. Innovative and sustainable diagnostic and therapeutic strategieso Advanced diagnostics: diagnostics in medicine is continuously evolving. In the last decades, huge steps forward have been done, particularly in the fields of imaging. However we have open issues which may create criticisms in the next future. The use of contrast agents, in particular, may become a problem, since they exploit elements which are not earth abundant; moreover, their indiscriminate release post-us may be critic for environment. We are going to promote the development and the step-up to the market of novel nanoparticles and contrast agents, able to improve the diagnostic performance and fix the issues of availability and sustainability of the classical CAs.67o Support to the development and advanced certification of medical devices: one of the most prominent requests from SMEs is the need of a support in the development of certified medical devices. In this context, the Spoke will assist local SMEs in this specific activity.o Regenerative medicine has become a novel and innovative field of medicine, which aims to repair damaged and aging tissues. In the present Spoke we are going to invest on this framework, with the specific objective of developing novel matrices and tissues helpful for tissue regeneration; moreover, we will support the technological transfer of these novel products to the marketo Drug Discovery Development and Delivery: novel technological strategies may be particularly helpful in the development of new drugs; however, beside this specific aspect, we will specifically investigate the field of drug delivery. Indeed, the development of systems able to assist drug delivery may be particularly helpful to improve the pharmacokinetics and pharmacodynamics properties of already available molecules. In this framework we will give the discovery background to assist the production of novel delivery systems by local and global enterprises.

    Paesi coinvolti

    • ITALIA

    Strutture interne coinvolte

  • SORveglianza GENomica in PiemonTE: sequenziamento di massa e analisi filogenomica di SARS CoV-2 e altri virus a carattere pandemico mediante metodi innovativi, automatici, a basso costo e alta efficienza, (2021-2023) - Responsabile Scientifico

    Ricerca Regionale

    ERC sectors

    LS7_9 - Public health and epidemiology PE1_21 - Application of mathematics in industry and society LS2_1 - Genomics, comparative genomics, functional genomics

    Abstract

    Per il controllo della pandemia da virus SARS-CoV-2 si impone lo studio del virus e delle sue varianti attraverso lo sviluppo di modelli innovativi di sorveglianza che, partendo da tecnologie di sequenziamento e analisi filogenetiche, possano essere applicati su larga scala per il monitoraggio della variabilità genetica del virus e per fornire in tempi rapidi l’analisi della circolazione del virus in rapporto a diversi contesti geografici e sociali. Tale Sorveglianza Genomica (SG) è disegnata per integrare in maniera efficace ed efficiente gli strumenti di sorveglianza tradizionali, che si fondano sull’analisi epidemiologica, il campionamento sistematico di contesti a rischio, come i focolai, e approfondimenti locali per il tracciamento e l’identificazione. Si istituisce un nuovo modello di sorveglianza genomica applicabile ai virus a carattere pandemico, e si sviluppano metodi bioinformatici ad elevata efficienza per l’analisi dei dati generati tramite COVseq, al fine di applicarla su larga scala per il sequenziamento e il monitoraggio del genoma di SARS-CoV-2 e delle varianti e di integrare il sistema di sorveglianza con gli aspetti genomici e virologici applicati su tutto il territorio della Regione Piemonte.

    Strutture interne coinvolte

  • IDEAS - Improving Design, Evaluation and Analysis of early drug development Studies, (2015-2018) - Responsabile Scientifico

    Ricerca UE - H2020 - Excellent Science - Marie Curie

    Vedi la scheda del progetto su CORDIS

    Abstract

    Drug development is a long and costly process which suffers from the major shortcoming that frequently failure is often onlydetermined during the final stage. Recently, it has been recognised that more care needs to be taken during the early stagesof development to avoid going into lengthy and costly confirmatory studies with ineffective or harmful treatments. To achievethis goal it is essential to implement efficient methods for the design and analysis of such early development studies. Theexpertise in this area is, however, limited at the moment and adequate methodology is only partially available. Using across-sectorial, transnational approach, the IDEAS network brings together leading public and private sector researchers inthe field with ample experience in training to educate, promote and support the future leaders in medical statistics in generaland in the design and analysis of early developmental studies in particular.Within the network, cross-sectorial, transnational teams will support young researchers with individual methodologicalprojects and devise an individually tailored training programme for them. Clinical advisors supplement the input of thesupervisory team and ensure practical relevance and uptake of the methods devised. The training activities are comprised ofa well-rounded mix of specialist, methodological components and generic, transferable skills. A mandatory set of networkwidetraining activities is supplemented by individual training components and cross-sectorial secondments, and particularattention is given to interaction and collaboration between researchers and supervisors across public and private sectorpartners. At the end of their training the researchers will be uniquely qualified with expertise in the field, benefit fromexperience in both public and private sector and can rely on a wide network of experts in the field in the future.

    Paesi coinvolti

    • Austria
    • Francia
    • Germania
    • Italia
    • Belgio

    Enti/Aziende coinvolti

    • MEDIZINISCHE UNIVERSITAET WIEN
    • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    • UNIVERSITAET BREMEN
    • INSTITUT CURIE
    • Bayer Pharma AG
    • POLITECNICO DI TORINO
    • JANSSEN PHARMACEUTICA NV

    Strutture interne coinvolte

  • Alcuni problemi statistici esplorativi nello sviluppo clinico e argomenti collegati, (2008-2010) - Responsabile Scientifico

    Ricerca Nazionale - PRIN

    Abstract

    Some explorative statistical problems inclinical development and related topics

    Paesi coinvolti

    • ITALIA

    Strutture interne coinvolte

    • Dipartimento di Matematica
  • Metodi statistici per la sperimentazione di tecniche di genomica comparativa, (2006-2008) - Responsabile Scientifico

    Ricerca Nazionale - PRIN

    Abstract

    Statistical methods for experimenting with comparative genomics techniques

    Paesi coinvolti

    • ITALIA

    Strutture interne coinvolte

    • Dipartimento di Matematica
  • TELERILEVAMENTO DI REFLUI INQUINANTI IN DIVERSE MATRICI AMBIENTALI, (2005-2010) - Responsabile Scientifico

    Ricerca Regionale

    Paesi coinvolti

    • ITALIA

    Enti/Aziende coinvolti

    • Regione Piemonte
    • POLITECNICO DI TORINO - AMMINISTRAZIONE CENTRALE

    Strutture interne coinvolte

    • Dipartimento di Automatica Informatica
    • Dipartimento di Matematica
  • Analisi Bayesiana e modelli grafici per dati di espressione genica, (2003-2005) - Responsabile Scientifico

    Ricerca Nazionale - PRIN

    Abstract

    Bayesian analysis and graphical models for gene expression data

    Paesi coinvolti

    • ITALIA

    Strutture interne coinvolte

    • Dipartimento di Matematica
  • Applicazioni farmaceutiche e ingegneristiche di modelli statistici per il controllo del rischio., (1999-2001) - Responsabile Scientifico

    Ricerca Nazionale - PRIN

    Abstract

    Pharmaceutical and engineering applications of statistical models for risk control

    Paesi coinvolti

    • ITALIA

    Strutture interne coinvolte

    • Dipartimento di Matematica
  • Vedi altro

Finanziati da contratti commerciali